Fda provides positive feedback to vistagen regarding use of the liebowitz social anxiety scale (lsas) as an endpoint in phase 3 development of fasedienol (ph94b) for treatment of social anxiety disorder

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced positive feedback from its recent engagement with the u.s.
VTGN Ratings Summary
VTGN Quant Ranking